Holen Sie sich die Stockscreener-App
32.59
0.87%
0.28
Handel nachbörslich:
32.59
Schlusskurs vom Vortag:
$32.31
Offen:
$32.46
24-Stunden-Volumen:
344.97K
Relative Volume:
0.68
Marktkapitalisierung:
$1.03B
Einnahmen:
$780.57M
Nettoeinkommen (Verlust:
$62.87M
KGV:
18.98
EPS:
1.7171
Netto-Cashflow:
$327.58M
1W Leistung:
+1.88%
1M Leistung:
-12.60%
6M Leistung:
-3.67%
1J Leistung:
+15.81%
1-Tages-Spanne:
$31.54
$33.00
1-Wochen-Bereich:
$31.54
$33.97
52-Wochen-Spanne:
$23.23
$50.79
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
Firmenname
Collegium Pharmaceutical Inc
Sektor
Telefon
781-713-3699
Adresse
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Compare COLL vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COLL
Collegium Pharmaceutical Inc
|
32.59 | 1.03B | 780.57M | 62.87M | 327.58M | 1.7171 |
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
118.26 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.92 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.82 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
559.65 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-01-10 | Hochstufung | Needham | Hold → Buy |
| 2024-07-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-06-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-05-10 | Herabstufung | Needham | Buy → Hold |
| 2024-05-10 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-01-04 | Herabstufung | Jefferies | Buy → Hold |
| 2023-08-25 | Bestätigt | Needham | Buy |
| 2023-05-02 | Fortgesetzt | Jefferies | Buy |
| 2022-08-08 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-02-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-14 | Eingeleitet | BWS Financial | Sell |
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-19 | Fortgesetzt | Jefferies | Buy |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-03 | Fortgesetzt | H.C. Wainwright | Buy |
| 2019-04-12 | Fortgesetzt | Janney | Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2019-01-16 | Bestätigt | Needham | Buy |
| 2018-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2018-02-07 | Bestätigt | Needham | Buy |
| 2017-12-05 | Bestätigt | Needham | Buy |
| 2017-09-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-05-11 | Bestätigt | Needham | Buy |
| 2016-09-13 | Eingeleitet | Gabelli & Co | Buy |
| 2015-06-01 | Eingeleitet | Jefferies | Buy |
| 2015-06-01 | Eingeleitet | Needham | Buy |
| 2015-06-01 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Collegium Pharmaceutical Inc Aktie (COLL) Neueste Nachrichten
Chipmakers Recap: Should I hold or sell Collegium Pharmaceutical Inc now2026 Highlights & Reliable Volume Spike Alerts - baoquankhu1.vn
COLL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Collegium Pharmaceutical (COLL) Valuation Check After Recent Share Price Pullback - Sahm
Is Collegium Pharmaceutical (COLL) one of the best small-cap drug manufacturers? - MSN
Collegium (COLL) EVP has 8,840 shares withheld for RSU tax payment - stocktitan.net
Collegium Pharmaceutical (COLL) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
GE HealthCare and Collegium Pharmaceutical Stocks Trade Down, What You Need To Know - Yahoo Finance
COLL Stock Price, Quote & Chart | COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) - ChartMill
Collegium Pharmaceutical (COLL) surged following record quarterly results - MSN
Collegium Pharmaceutical, Inc. (COLL) Stock Forecasts - Yahoo Finance
Collegium Pharmaceutical EVP Sells Nearly 50,000 Shares Worth $2 Million - AOL.com
Collegium Pharma Executive David Dieter Sells Shares in March 2026News and Statistics - IndexBox
Collegium Pharmaceutical Acquires AZSTARYS for $650M - National Today
Is Collegium Pharmaceutical (COLL) One of the Best Small-Cap Drug Manufacturers - Insider Monkey
Aug Volume: Can Collegium Pharmaceutical Inc be the next market leaderSell Signal & AI Enhanced Trading Alerts - baoquankhu1.vn
JPMorgan Chase & Co. Acquires 139,689 Shares of Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHD - The Motley Fool
Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHD - The Motley Fool
Wedge Capital Management L L P NC Acquires New Stake in Collegium Pharmaceutical, Inc. $COLL - marketbeat.com
Published on: 2026-03-30 05:44:15 - baoquankhu1.vn
Collegium Pharmaceutical Inc (NASDAQ:COLL) Presents a Compelling Value Investment Case - ChartMill
COLL SEC FilingsCollegium Pharmaceutical Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is It Time To Reassess Collegium Pharmaceutical (COLL) After The Recent Share Price Pullback? - simplywall.st
Collegium’s AZSTARYS Deal And Insider Sale Put Focus On Valuation - Yahoo Finance
Vanguard disaggregates holdings; reports 0 shares in Collegium (COLL) - Stock Titan
Branded Pharmaceuticals Stocks Q4 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL) - Yahoo Finance
Collegium Pharmaceutical, Inc. $COLL Shares Bought by Assenagon Asset Management S.A. - marketbeat.com
Collegium Pharmaceutical, Inc. (COLL) to Present 9 Pain Studies at PAINWeek 2025 - MSN
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), Medline (MDLN) and Collegium Pharmaceutical (COLL) - The Globe and Mail
Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate GrowthSlideshow (NASDAQ:COLL) 2026-03-24 - Seeking Alpha
Collegium Pharmaceutical Stock Gains Momentum After Key Debt Repayment and Strong Earnings Momentum - ad-hoc-news.de
Collegium Pharmaceutical (COLL) Valuation Check After Recent Share Price Volatility - Sahm
Collegium to buy ADHD medicine Azstarys for up to $785M - MSN
Insider Selling: Collegium Pharmaceutical (NASDAQ:COLL) EVP Sells 13,976 Shares of Stock - MarketBeat
Dieter David, Collegium Pharmaceutical EVP, sells $488k in stock By Investing.com - Investing.com Canada
Dieter David, Collegium Pharmaceutical EVP, sells $488k in stock - investing.com
Collegium (NASDAQ: COLL) EVP trades 13,976 shares under 10b5-1 plan - Stock Titan
Collegium Pharmaceuticals: Another M&A Episode Adds To An Intriguing Case (NASDAQ:COLL) - Seeking Alpha
Collegium Pharmaceutical stock faces scrutiny amid opioid market shifts and regulatory pressures - AD HOC NEWS
Pharma M&A Roundup: Novartis to Acquire Pan-Mutant-Selective PI3Kα Inhibitor from Synnovation Therapeutics, Collegium to Acquire Azstarys from Corium Therapeutics - Pharmaceutical Executive
Azstarys (re-)born with Collegium’s ADHD buy - BioWorld MedTech
Collegium Pharmaceutical Expands ADHD Portfolio With AZSTARYS And Valuation Gap - simplywall.st
Needham & Company LLC Reiterates Buy Rating for Collegium Pharmaceutical (NASDAQ:COLL) - MarketBeat
Collegium Pharmaceutical (NASDAQ:COLL) Given Buy Rating at HC Wainwright - MarketBeat
Collegium to acquire Azstarys from Corium Therapeutics - The Pharma Letter
Collegium Pharmaceutical to Acquire AZSTARYS® for $650 Million, Expanding ADHD Portfolio and Projecting Over $50 Million Revenue in Late 2026 - Minichart
Collegium Pharmaceutical to acquire AZSTARYS for $650 million By Investing.com - Investing.com Australia
Jefferies reiterates Collegium Pharmaceutical stock Buy on ADHD deal By Investing.com - Investing.com Canada
Collegium Pharmaceutical to Acquire AZSTARYS ADHD Franchise - TipRanks
Collegium (NASDAQ: COLL) to acquire AZSTARYS in $650M ADHD expansion deal - Stock Titan
Finanzdaten der Collegium Pharmaceutical Inc-Aktie (COLL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.35%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):